不能手术的局部晚期或转移性胰腺癌患者用吉西他滨的疗效及预后因素

查看全文 作　　者：Sezgin [1]C.;Karabulut [1]B.;Uslu [1]R.;E. [2]Goker.;王铮(译)[1];陈云茹(校)[1] 机构地区：[1]不详;[2]Ege University School of Medicine, Division of Medical Oncology, Tulay Aktas Oncology Hospital, 35100 Bornova/Izmir, Turkey 出　　处：《世界核心医学期刊文摘(胃肠病学分册)》索引2006年第2卷第6期,共2页 摘　　要：Objective. Most patients with pancreatic cancer show an inoperable locally advanced/ metastatic tumour at the time of diagnosis. The present study was aimed at determining the prognostic factors in patients with advanced pancreatic carcinoma treated with gemcitabine. Material and methods. Sixty-seven unresectable or metastatic pancreatic cancer patients treated with gemcitabine were included in the study and a total of 258 cycles of treatment were applied. Results. The overall response rate was 5%. Thirty-one percent of the patients had stable disease, whereas progressive disease was seen in 49%. Clinical benefit response rate was 15%. The median duration of response was 7.3 months. Median progression-free survival was 3 months, while median overall survival was 9 months. Univariate analysis revealed that worse results were found in patients with performance status (PS) =2, and in patients with primary tumour location in the body or tail of the pancreas (p < 0.05). Multivariate analysis of data revealed that the most important factor was PS of the patient, as the patients with PS =2 had worse results than the patients with PS =0-1 (p < 0.05). Conclusions. Low PS is a negative predictive factor for the survival of patients with advanced pancreatic carcinoma treated with gemcitabine. 关 键 词：胰腺癌患者 预后因素 吉西他滨 局部晚期 转移性 手术 多变量分析 疗效 中位时间